Clinical effect of single use or combination of dydrogesterone and progestin in treatment of threatened abortion caused by uteal phase defect
10.7501/j.issn.1674-6376.2017.03.019
- VernacularTitle:地屈孕酮与黄体酮单药或联用治疗黄体功能不全型先兆流产的临床研究
- Author:
Lili FAN
;
Xiuzhen XUE
;
Yongyong ZHANG
;
Na JIAO
- Keywords:
threatened abortion caused by uteal phase defect;
dydrogesterone;
progestin;
P;
E2;
hCG
- From:
Drug Evaluation Research
2017;40(3):381-384
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the clinical effect of single use or combination of dydrogesterone and progestin in treatment of threatened abortion caused by uteal phase defect.Methods Totally 186 patients with threatened abortion caused by uteal phase defect accepted in The First Affiliated Hospital of Henan from April 2015 to April 2016 were selected and randomly divided into groups A,B,and C with 62 cases in each group.Patients in group A were given dydrogesterone,those in group B were given progestin,and those in group C were given dydrogesterone combined with progestin.Then the clinical effect,expression of hormones,treatment outcome,and adverse reaction were observed and compared.Results The total effective rates of groups A and B were 72.58% and 66.13%,respectively,which were obviously lower than 90.32% of group C with statistically significance (P <0.05).The expression levels of P,E2,and hCG of three groups after treatment were higher than those before,those in group C were the highest among them (P < 0.05).The successful treatment rates of groups A,B,and C were 83.87%,82.26%,and 95.16%,respectively,which had no great difference.Conclusion Combination use of dydrogesterone and progestin has better effective rate in treatment of threatened abortion caused by uteal phase defect compared to single use of these two drugs,which has good safety and worth of clinical application.